EYEG News and Press, Eyegate Pharmaceuticals Inc. From 01/06/20

EyeGate Pharmaceuticals (NASDAQ: EYEG ) hits the enrollment target in a follow-on pilot study evaluating its Ocular Bandage Gel eye drop in patients with punctate epitheliopathies, mainly dry eye. More news on: EyeGate Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...

Aimmune Therapeutics, Inc. (AIMT) has been quite a sprightly stock lately, and it has a couple of key events coming up as well. However, the firm also faces a few obstacles, the foremost being the FDA's stepmotherly attitude over the years. Its lead drug candidate Palforzia was approved by t...

WALTHAM, MA / ACCESSWIRE / January 3, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced the completion of its previously announced registered direct offer...

Gainers: Neovasc (NASDAQ: NVCN )  +70% . More news on: Neovasc Inc., Inpixon, FuelCell Energy, Inc., Stocks on the move, Read more ...

WALTHAM, MA / ACCESSWIRE / December 31, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, today announced that it has entered into a definitive agreement with certain ins...

Gainers: Savara (NASDAQ: SVRA )  +98% . More news on: Savara Inc., NIO Limited, Sol-Gel Technologies Ltd., Stocks on the move, Read more ...

WALTHAM, MA / ACCESSWIRE / December 17, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company") announced today that it has received approximately $1.9 million from the exercise of warrants subsequent to the release of positive topline data on November 22, 2019 for it...

Image Source: OPIS Company Thesis EyeGate's ( EYEG ) recent Phase 3 interim data release on its lead candidate, Ocular Bandage Gel, demonstrated significant evidence favoring the drug's approval. Its formulation as an eye drop instead of a contact lens should also aid in sales and ...

WALTHAM, MA / ACCESSWIRE / December 2, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received additional positive topline data in its corn...

Positive Pivotal Top-Line data EyeGate Pharmaceuticals, Inc . ( EYEG ) is a clinical stage specialty pharmaceutical company that develops products for treating eye diseases and disorders. On Nov 22, 2019, EYEG announced that their PRK (photorefractive keratectomy) study has met its pr...